Day: November 27, 2020

FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate at two upcoming virtual investor conferences in December, including:Evercore ISI 3rd Annual HealthCONx ConferenceDate: December 1, 2020Live Presentation Time: 10:55 am ETPiper Sandler 32nd Annual Virtual Healthcare ConferenceDate: December 2, 2020Pre-recorded presentation available onlineExecutive management will also participate in one-on-one meetings during the duration of the conferences.To access the live webcast and archived recordings for each presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations....

MONTREAL, Nov. 27, 2020 (GLOBE NEWSWIRE) — NanoXplore Inc. (“NanoXplore” or the “Corporation”) (TSX-V: GRA and OTCQX: NNXPF) is pleased to announce the appointment of Jodie Morgan to its Board of Directors.Ms. Morgan has an impressive background as a strategic President and CEO and Board member of several companies, including currently as a Director of Bartek Ingredients Inc., the world’s largest producer of malic acid and food-grade fumaric acid—specialty products that improve flavour profiles, food safety and profitability in foods and beverages, among other things. She is also currently the CEO and a Director of GreenMantra, an upcycling technology leader in the circular economy of plastics. Ms. Morgan is a member of the National Association of Corporate Directors and Women Corporate Directors in the United States...

MONTRÉAL, 27 nov. 2020 (GLOBE NEWSWIRE) — NanoXplore Inc. (« NanoXplore » ou la « Société ») (TSX-V: GRA et OTCQX: NNXPF) a le plaisir d’annoncer la nomination de Jodie Morgan à son conseil d’administration.Mme Morgan a une expérience impressionnante en tant que présidente et chef de la direction et membre du conseil d’administration de plusieurs entreprises, y compris actuellement en tant qu’administratrice de Bartek Ingredients Inc., le plus grand producteur mondial d’acide malique et d’acide fumarique de qualité alimentaire – des produits spécialisés qui améliorent la saveur, la sécurité alimentaire et la rentabilité des aliments et des boissons, entre autres. Elle est également chef de la direction et administratrice de GreenMantra, un leader de la technologie « upcycling » dans l’économie...

VANCOUVER, British Columbia, Nov. 27, 2020 (GLOBE NEWSWIRE) — Cypress Development Corp. (TSX-V: CYP) (OTCQB: CYDVF) (Frankfurt: C1Z1) (“Cypress” or “the Company”) announces the Company has reached an agreement with Pasinex Resources Limited (CSE: PSE) (“Pasinex”) and Caliber Minerals Inc. to change the terms relating to the earn-in option agreement on Cypress’ Gunman (formally Spur) zinc exploration property in Nevada, USA.The agreement extends the deadline to complete the conditions to earn an initial 51% interest in the Gunman Project to December 31, 2022 and extends the deadline to complete the conditions to earn an additional 29% interest in the Gunman Project to December 31, 2024.As a condition precedent for the effectiveness of the agreement and as a binding and unconditional material obligation, Pasinex shall incur a minimum...

TORONTO, Nov. 27, 2020 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc. (“Dialco”), today announced the details for the Company’s upcoming Virtual Investor Day, scheduled to be held on Friday, December 4, 2020 at 10:00 a.m. EST.Members of Spectral’s leadership team will provide a detailed status update on the progress of the Tigris trial as well as the approvals and advancements towards commercialization at Dialco. In addition, the Company will provide commentary on its balance sheet and the capital markets environment.To preregister for the webcast presentation,...

NEW YORK, Nov. 27, 2020 (GLOBE NEWSWIRE) — Trident Acquisitions Corp. (NASDAQ: TDACU, TDAC, TDACW) (“Trident”), a special purpose acquisition company, announced that it has filed a proxy supplement to its annual meeting proxy statement (the “Supplement”). The Supplement explains certain changes to the terms under which Trident can extend its available time to complete a business combination. If stockholders approve the amendment to Trident’s certificate of incorporation at the November 30, 2020 stockholder’s meeting (the “Annual Meeting”), which allows Trident the ability to extend the date by which it has to complete a business combination by an additional three months and with an ability to further extend for an additional three months if approved by Trident’s board of directors, Trident will be required to deposit additional...

MALVERN, Pa., Nov. 27, 2020 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on “The Promise of Cell & Gene Therapies: Regulatory and Reimbursement Roadblocks” at Xconomy’s Xcelerating Life Sciences New York & Philadelphia Virtual Event on December 3 at 10:30 a.m. This panel will be moderated by Theresa Lavoie, Principal, Fish & Richardson and also feature panelists, Greg White, Senior Director, Global Market Access Policy – Janssen, Pharmaceutical Companies and Snehal Naik, Global Regulatory Affair- Advanced Therapies, Janssen R&D.About Ocugen, Inc.Ocugen, Inc. is a biopharmaceutical company...

SÃO PAULO, Brazil, Nov. 27, 2020 (GLOBE NEWSWIRE) — XP Inc., or XP, a leading, technology-driven platform and a trusted provider of low-fee financial products and services in Brazil, today commented, following the material fact released to the market on November 26, 2020, or the material fact, by Itaú Unibanco Holding S.A., or Itaú, in which Itaú communicated (i) the approval by its board of directors of the spin-off of its investment in XP, which will be segregated into a newly formed company, or Newco, whose only assets would be common shares of XP representing 41.05% of XP’s share capital, and (ii) the potential sale by Itaú of 5% of XP’s share capital, as previously communicated by Itaú on November 3, 2020, that XP has initiated studies on possible corporate structures that seek to maintain the interests of Itaú aligned with...

— Indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing —— Approval supports company’s approach to address rare genetic diseases of obesity associated with an impaired MC4 receptor pathway —— People living with these rare genetic diseases of obesity struggle with insatiable hunger and excessive weight gain beginning at a young age —— Approval based on data from two 52-week open-label trials that demonstrated clinically meaningful and statistically significant weight loss and reduction of hunger —— Rare Pediatric Disease Priority Review Voucher issued to Rhythm by FDA —— Company to host conference call today at 9:30 a.m. ET —BOSTON, Nov. 27, 2020...